TapewireFind a company

person · Reporting owner

KELLEY JOHN J III

Disclosed activity across 2 companies

Tapewire entity
73014
SEC CIK
0001562224

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BEAZER HOMES USA INCBZH · Entity 5036DirectorNovember 17, 2025November 18, 2025
EQUIFAX INCEFX · Entity 3235EVP, Chief Legal OfficerFebruary 11, 2025February 13, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BEAZER HOMES USA INC

Report date November 17, 2025 · Filed November 18, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect23,116 Reported balance After 2025-11-17 transaction · row 1
1 source row

Row 1 · 2025-11-17 · Grant · Acquired 7,199 · Balance 23,116

F1: Restricted stock award scheduled to vest on the first anniversary of grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock award scheduled to vest on the first anniversary of grant date.

EQUIFAX INC

Report date February 11, 2025 · Filed February 13, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect15,175 Last balance in matching sequence After 2025-02-11 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2025-02-11 · Grant · Acquired 2,710 · Balance 17,202

F1: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Row 2 · 2025-02-11 · Tax withholding · Disposed 2,027 · Balance 15,175

F1: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Filing footnotes · ownership attribution and instrument terms

F1: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 26, 2022 Filed Oct 28, 2022 20:12 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 510 $163.35 $83,308.25
Disclosure

SEC source: 0001225208-22-011214 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,049

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 8/24/2022.

F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $162.94 to $163.91, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
October 26, 2022 Filed Oct 28, 2022 20:12 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 483 $162.25 $78,364.72
Disclosure

SEC source: 0001225208-22-011214 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,559

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 8/24/2022.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $161.79 to $162.67, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 22, 2022 Filed Feb 24, 2022 21:11 UTC EQUIFAX INC EFX · Entity 3235 Tax withholdingCommon Stock 9,017 $212.24 $1,913,768.08
Disclosure

SEC source: 0001225208-22-003264 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,011

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 22, 2022 Filed Feb 24, 2022 21:11 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 17,497 $0.00 $0.00
Disclosure

SEC source: 0001225208-22-003264 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,028

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 11, 2022 Filed Feb 15, 2022 22:33 UTC EQUIFAX INC EFX · Entity 3235 GrantStock Option/Right to Buy · Derivative 7,109 $0.00 Strike: $225.00 $0.00
Disclosure

SEC source: 0001225208-22-002187 · doc4.xml · derivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,109

Underlying: Common Stock · 7,109 shares

Expires 2032-02-11

F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 2/11/2023.

Read SEC document
February 11, 2022 Filed Feb 15, 2022 22:33 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 1,778 $0.00 $0.00
Disclosure

SEC source: 0001225208-22-002187 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,531

F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/11/2025.

F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 21:42 UTC EQUIFAX INC EFX · Entity 3235 Exercise / conversionStock Option/Right to Buy · Derivative 2,761 $0.00 Strike: $191.44 $0.00
Disclosure

SEC source: 0001225208-22-000214 · doc4.xml · derivative · entry 5

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,523

Underlying: Common Stock · 2,761 shares

Expires 2026-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests in three equal annual increments beginning 2/21/2021.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 21:42 UTC EQUIFAX INC EFX · Entity 3235 Exercise / conversionStock Option/Right to Buy · Derivative 2,188 $0.00 Strike: $175.48 $0.00
Disclosure

SEC source: 0001225208-22-000214 · doc4.xml · derivative · entry 4

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,378

Underlying: Common Stock · 2,188 shares

Expires 2026-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests in three equal annual increments beginning 2/21/2021.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 21:42 UTC EQUIFAX INC EFX · Entity 3235 Tax withholdingCommon Stock 3,950 $291.54 $1,151,583.00
Disclosure

SEC source: 0001225208-22-000214 · doc4.xml · nonDerivative · entry 3

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,753

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 21:42 UTC EQUIFAX INC EFX · Entity 3235 Exercise / conversionCommon Stock 2,188 $175.48 $383,950.24
Disclosure

SEC source: 0001225208-22-000214 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 21:42 UTC EQUIFAX INC EFX · Entity 3235 Exercise / conversionCommon Stock 2,761 $191.44 $528,565.84
Disclosure

SEC source: 0001225208-22-000214 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,515

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
August 20, 2021 Filed Aug 24, 2021 20:13 UTC EQUIFAX INC EFX · Entity 3235 Exercise / conversionStock Option/Right to Buy · Derivative 16,196 $0.00 Strike: $123.49 $0.00
Disclosure

SEC source: 0001225208-21-011701 · doc4.xml · derivative · entry 5

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,196 shares

Expires 2028-07-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 5/27/2021.

F6 · derivative.exercise_date: The option vested in three equal annual increments beginning 7/27/2019.

Read SEC document
August 20, 2021 Filed Aug 24, 2021 20:13 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 12,722 $257.12 $3,271,041.20
Disclosure

SEC source: 0001225208-21-011701 · doc4.xml · nonDerivative · entry 4

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,738

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 5/27/2021.

F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $256.655 to $257.61, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
August 20, 2021 Filed Aug 24, 2021 20:13 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 10,623 $256.16 $2,721,137.75
Disclosure

SEC source: 0001225208-21-011701 · doc4.xml · nonDerivative · entry 3

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,460

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 5/27/2021.

F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $255.645 to $256.62, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
August 20, 2021 Filed Aug 24, 2021 20:13 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 1,755 $257.73 $452,321.06
Disclosure

SEC source: 0001225208-21-011701 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,083

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 5/27/2021.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $257.63 to $258.50, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
August 20, 2021 Filed Aug 24, 2021 20:13 UTC EQUIFAX INC EFX · Entity 3235 Exercise / conversionCommon Stock 16,196 $123.49 $2,000,044.04
Disclosure

SEC source: 0001225208-21-011701 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,838

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 5/27/2021.

F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
July 27, 2021 Filed Jul 29, 2021 20:18 UTC EQUIFAX INC EFX · Entity 3235 Tax withholdingCommon Stock 1,887 $258.29 $487,393.23
Disclosure

SEC source: 0001225208-21-010925 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,642

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
May 25, 2021 Filed May 27, 2021 20:11 UTC EQUIFAX INC EFX · Entity 3235 Exercise / conversionStock Option/Right to Buy · Derivative 8,859 $0.00 Strike: $121.35 $0.00
Disclosure

SEC source: 0001225208-21-008588 · doc4.xml · derivative · entry 5

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,859 shares

Expires 2028-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested in three equal annual increments beginning 3/5/2019.

Read SEC document
May 25, 2021 Filed May 27, 2021 20:11 UTC EQUIFAX INC EFX · Entity 3235 Exercise / conversionStock Option/Right to Buy · Derivative 8,279 $0.00 Strike: $129.93 $0.00
Disclosure

SEC source: 0001225208-21-008588 · doc4.xml · derivative · entry 4

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,279 shares

Expires 2027-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested in three equal annual increments beginning 2/16/2018.

Read SEC document
May 25, 2021 Filed May 27, 2021 20:11 UTC EQUIFAX INC EFX · Entity 3235 Tax withholdingCommon Stock 12,734 $235.94 $3,004,459.96
Disclosure

SEC source: 0001225208-21-008588 · doc4.xml · nonDerivative · entry 3

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,512

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
May 25, 2021 Filed May 27, 2021 20:11 UTC EQUIFAX INC EFX · Entity 3235 Exercise / conversionCommon Stock 8,279 $129.93 $1,075,690.47
Disclosure

SEC source: 0001225208-21-008588 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,246

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
May 25, 2021 Filed May 27, 2021 20:11 UTC EQUIFAX INC EFX · Entity 3235 Exercise / conversionCommon Stock 8,859 $121.35 $1,075,039.65
Disclosure

SEC source: 0001225208-21-008588 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,967

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:09 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 3,570 $238.38 $851,017.67
Disclosure

SEC source: 0001225208-21-008119 · doc4.xml · nonDerivative · entry 3

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,108

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/25/2021.

F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $237.725 to $238.71, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:09 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 1,361 $237.20 $322,822.80
Disclosure

SEC source: 0001225208-21-008119 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,678

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/25/2021.

F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $236.69 to $237.64, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:09 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 1,203 $236.02 $283,928.81
Disclosure

SEC source: 0001225208-21-008119 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,039

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/25/2021.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $235.62 to $236.375, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:20 UTC EQUIFAX INC EFX · Entity 3235 Tax withholdingCommon Stock 4,430 $169.75 $751,992.50
Disclosure

SEC source: 0001225208-21-004920 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,215

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:20 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 7,523 $0.00 $0.00
Disclosure

SEC source: 0001225208-21-004920 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,645

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 12, 2021 Filed Feb 17, 2021 22:23 UTC EQUIFAX INC EFX · Entity 3235 GrantStock Option/Right to Buy · Derivative 6,773 $0.00 Strike: $177.19 $0.00
Disclosure

SEC source: 0001225208-21-002796 · doc4.xml · derivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,773

Underlying: Common Stock · 6,773 shares

Expires 2031-02-12

F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 2/12/2022.

Read SEC document
February 12, 2021 Filed Feb 17, 2021 22:23 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 1,693 $0.00 $0.00
Disclosure

SEC source: 0001225208-21-002796 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,122

F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/12/2024.

F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
May 11, 2020 Filed May 13, 2020 20:16 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 7,670 $147.94 $1,134,707.47
Disclosure

SEC source: 0001225208-20-007576 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,357

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on February 25, 2020.

F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $147.355 to $148.335, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
May 11, 2020 Filed May 13, 2020 20:16 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 4,830 $148.93 $719,336.73
Disclosure

SEC source: 0001225208-20-007576 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,027

F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on February 25, 2020.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $148.38 to $149.72, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 21, 2020 Filed Feb 25, 2020 21:55 UTC EQUIFAX INC EFX · Entity 3235 GrantStock Option/Right to Buy · Derivative 6,566 $0.00 Strike: $175.48 $0.00
Disclosure

SEC source: 0001225208-20-003454 · doc4.xml · derivative · entry 3

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,566

Underlying: Common Stock · 6,566 shares

Expires 2026-02-21

F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 2/21/2021.

Read SEC document
February 21, 2020 Filed Feb 25, 2020 21:55 UTC EQUIFAX INC EFX · Entity 3235 GrantStock Option/Right to Buy · Derivative 8,284 $0.00 Strike: $191.44 $0.00
Disclosure

SEC source: 0001225208-20-003454 · doc4.xml · derivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,284

Underlying: Common Stock · 8,284 shares

Expires 2026-02-21

F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 2/21/2021.

Read SEC document
February 21, 2020 Filed Feb 25, 2020 21:55 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 1,881 $0.00 $0.00
Disclosure

SEC source: 0001225208-20-003454 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,828

F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/21/2023.

F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 19, 2020 Filed Feb 21, 2020 21:12 UTC EQUIFAX INC EFX · Entity 3235 Tax withholdingCommon Stock 565 $161.88 $91,462.20
Disclosure

SEC source: 0001225208-20-003094 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,947

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 19, 2020 Filed Feb 21, 2020 21:12 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 1,252 $0.00 $0.00
Disclosure

SEC source: 0001225208-20-003094 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,512

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 16, 2020 Filed Feb 19, 2020 22:03 UTC EQUIFAX INC EFX · Entity 3235 Tax withholdingCommon Stock 967 $159.63 $154,362.21
Disclosure

SEC source: 0001225208-20-002781 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,260

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 22, 2019 Filed Feb 27, 2019 01:30 UTC EQUIFAX INC EFX · Entity 3235 GrantStock Option/Right to Buy · Derivative 13,150 $0.00 Strike: $127.37 $0.00
Disclosure

SEC source: 0001225208-19-003793 · doc4.xml · derivative · entry 4

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,150

Underlying: Common Stock · 13,150 shares

Expires 2025-02-22

F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022.

Read SEC document
February 22, 2019 Filed Feb 27, 2019 01:30 UTC EQUIFAX INC EFX · Entity 3235 GrantStock Option/Right to Buy · Derivative 15,899 $0.00 Strike: $138.45 $0.00
Disclosure

SEC source: 0001225208-19-003793 · doc4.xml · derivative · entry 3

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,899

Underlying: Common Stock · 15,899 shares

Expires 2025-02-22

F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022.

Read SEC document
February 22, 2019 Filed Feb 27, 2019 01:30 UTC EQUIFAX INC EFX · Entity 3235 GrantStock Option/Right to Buy · Derivative 19,172 $0.00 Strike: $149.53 $0.00
Disclosure

SEC source: 0001225208-19-003793 · doc4.xml · derivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,172

Underlying: Common Stock · 19,172 shares

Expires 2025-02-22

F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022.

Read SEC document
February 22, 2019 Filed Feb 27, 2019 01:30 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 2,426 $0.00 $0.00
Disclosure

SEC source: 0001225208-19-003793 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,099

F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/22/2022.

F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 18, 2019 Filed Feb 20, 2019 21:50 UTC EQUIFAX INC EFX · Entity 3235 Tax withholdingCommon Stock 2,310 $109.32 $252,529.20
Disclosure

SEC source: 0001225208-19-003071 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,673

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 18, 2019 Filed Feb 20, 2019 21:50 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 1,817 $0.00 $0.00
Disclosure

SEC source: 0001225208-19-003071 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,983

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
July 27, 2018 Filed Jul 31, 2018 20:52 UTC EQUIFAX INC EFX · Entity 3235 GrantStock Option/Right to Buy · Derivative 16,196 $0.00 Strike: $123.49 $0.00
Disclosure

SEC source: 0001225208-18-012075 · doc4.xml · derivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,196

Underlying: Common Stock · 16,196 shares

Expires 2028-07-27

F3 · derivative.exercise_date: Special equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 7/27/2019.

Read SEC document
July 27, 2018 Filed Jul 31, 2018 20:52 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 4,049 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-012075 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,109

F1 · security: Special equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 7/27/2021.

F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
March 05, 2018 Filed Mar 7, 2018 22:19 UTC EQUIFAX INC EFX · Entity 3235 GrantStock Option/Right to Buy · Derivative 8,859 $0.00 Strike: $121.35 $0.00
Disclosure

SEC source: 0001225208-18-005688 · doc4.xml · derivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · CVP, CLO & CS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,859

Underlying: Common Stock · 8,859 shares

Expires 2028-03-05

F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 3/5/2019.

Read SEC document
March 05, 2018 Filed Mar 7, 2018 22:19 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 2,215 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-005688 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · CVP, CLO & CS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,033

F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 3/5/2021.

F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 19, 2018 Filed Feb 21, 2018 22:36 UTC EQUIFAX INC EFX · Entity 3235 Tax withholdingCommon Stock 7,129 $117.46 $837,372.34
Disclosure

SEC source: 0001225208-18-003601 · doc4.xml · nonDerivative · entry 2

KELLEY JOHN J III · CIK 0001562224 · CVP, CLO & CS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,818

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in the corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 19, 2018 Filed Feb 21, 2018 22:36 UTC EQUIFAX INC EFX · Entity 3235 GrantCommon Stock 12,133 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-003601 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · CVP, CLO & CS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,947

F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in the corresponding restricted stock units through the Company's last dividend payment date.

Read SEC document
February 28, 2017 Filed Mar 2, 2017 20:59 UTC EQUIFAX INC EFX · Entity 3235 SaleCommon Stock 8,500 $130.85 $1,112,200.35
Disclosure

SEC source: 0001225208-17-005278 · doc4.xml · nonDerivative · entry 1

KELLEY JOHN J III · CIK 0001562224 · CVP, CLO & CS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,787

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $130.81 to $130.96, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.